Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May/Jun;42(3):392-399.
doi: 10.1097/AAP.0000000000000553.

Reporting of Design Features and Analysis Details in Randomized Clinical Trials of Procedural Treatments for Cancer Pain: An ACTTION Systematic Review

Daniel Rothstein  1 , Rachel A Kitt, Shannon M Smith, Salahadin Abdi, Mitchell P Engle, Michael P McDermott, Srinivasa N Raja, Dennis C Turk, Robert H Dworkin, Jennifer S Gewandter
Affiliations

Reporting of Design Features and Analysis Details in Randomized Clinical Trials of Procedural Treatments for Cancer Pain: An ACTTION Systematic Review

Daniel Rothstein et al. Reg Anesth Pain Med. 2017 May/Jun.

Abstract

Background and objectives: The objective of this study was to assess the reporting of randomized clinical trials investigating procedural treatments (eg, nerve blocks, targeted drug delivery) for cancer pain, with a focus on aspects that are particularly challenging in these trials.

Methods: This article presents results from a systematic review of reporting of randomized clinical trials of procedural interventions for cancer pain. Articles were identified by searching PubMed from 1966 to June 2014. Data related to quality of reporting are presented for early (1985-2004) and late periods (2005-2014).

Results: A total of 35 published trials were included. Approximately two-thirds of the articles clearly indicated the level of blinding. Only 26% reported a primary outcome measure. Less than half explicitly reported the number of patients who completed the trial, and only 1 reported a method that was used to accommodate missing data. Almost one-third of articles included a responder analysis, all of which specified the definition of a responder.

Conclusions: The goal of highlighting these deficiencies in reporting is to promote transparent reporting of details affecting the completion and interpretation of procedural cancer pain trials so that their quality can be more easily evaluated.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA diagram
See this image and copyright information in PMC

References

    1. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 2001;93:247–257. - PubMed
    1. Christo PJ, Mazloomdoost D. Interventional pain treatments for cancer pain. Annals of NY Acad Sci 2008;1138:299–328. - PubMed
    1. Eidelman A, White T, Swarm RA. Interventional therapies for cancer pain management: important adjuvants to systemic analgesics. JNCCN. 2007;5:753–760. - PubMed
    1. Fleming TR. Clinical trials: discerning hype from substance. Annals of Int Med 2010;153:400–406. - PMC - PubMed
    1. Gewandter JS, Smith SM, McKeown A, et al. Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTTION systematic review and recommendations. Pain. 2014;155:461–466. - PubMed

Publication types